SEC Form 4 · accession 0001209191-16-100267
Insight Molecular Diagnostics Inc. · IMDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Arno
Director
Period of report
Feb 16, 2016
Accepted (ET)
Feb 18, 2016 · 8:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001642380
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $3.06 | Feb 16, 2016 | A | 20,000 | A | — | Feb 15, 2026 | Common Stock | 20,000 | 20,000 | D |
| Option to Purchase Common StockF2 | $2.20 | holding | — | — | — | — | Jun 29, 2025 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1Will become exercisable in four equal installments at the end of each calendar quarter based upon continued service on the board of directors from the date of grant.
- F22,500 options became exercisable on September 30, 2015 and December 31, 2015, and the remaining 5,000 options will become exercisable in 2 equal quarterly installments based upon continued service on the board of directors.